Affiliation:
1. Department of Anatomy, Histology, Forensic Medicine and Orthopedics, Unit of Histology and Medical Embryology Sapienza University Rome Italy
2. Department of Pharmacology University of Oxford Oxford UK
3. Department of Pharmacology, College of Pharmacy Jazan University Jazan Saudi Arabia
Abstract
AbstractThe ion channel two‐pore channel 2 (TPC2), localised on the membranes of acidic organelles such as endo‐lysosomes and melanosomes, has been shown to play a role in pathologies including cancer, and it is differently expressed in primary versus metastatic melanoma cells. Whether TPC2 plays a pro‐ or anti‐oncogenic role in different tumour conditions is a relevant open question which we have explored in melanoma at different stages of tumour progression. The behaviour of primary melanoma cell line B16F0 and its metastatic subline B16F10 were compared in response to TPC2 modulation by silencing (by small interfering RNA), knock‐out (by CRISPR/Cas9) and overexpression (by mCherry‐TPC2 transfected plasmid). TPC2 silencing increased cell migration, epithelial‐to‐mesenchymal transition and autophagy in the metastatic samples, but abated them in the silenced primary ones. Interestingly, while TPC2 inactivation failed to affect markers of proliferation in both samples, it strongly enhanced the migratory behaviour of the metastatic cells, again suggesting that in the more aggressive phenotype TPC2 plays a specific antimetastatic role. In line with this, overexpression of TPC2 in B16F10 cells resulted in phenotype rescue, that is, a decrease in migratory ability, thus collectively resuming traits of the B16F0 primary cell line. Our research shows a novel role of TPC2 in melanoma cells that is intriguingly different in initial versus late stages of cancer progression.